Epix Initiates Phase IIb Right-Heart Catheterization Study of PRX-08066
Posted on: Friday, 15 August 2008, 09:00 CDT
Epix Pharmaceuticals has initiated its Phase IIb right-heart catheter study of PRX-08066 in patients with chronic obstructive pulmonary disease and moderate-to-severe pulmonary hypertension.
PRX-08066 is a serotonin type 2B receptor (5-HT2B) antagonist that may represent a new mechanism of action for treating pulmonary hypertension (PH).
This single-arm, open-label, Phase IIb study is designed to evaluate the mean pulmonary artery blood pressure change from baseline as measured directly by right-heart catheterization and will also measure the change from baseline in the standard six-minute walk distance test after three months of treatment. Patients will be treated with 500mg of PRX-08066 on day one of the trial followed by twice-daily dosing of 300mg of PRX-08066 for three months. The trial is designed to enroll adult patients with chronic obstructive pulmonary disease (COPD) and moderate-to-severe PH.
Elkan Gamzu, interim CEO of Epix, said: "There are currently no approved drugs to treat PH associated with COPD and it is estimated that this disease may affect up to six million people worldwide. These patients have a very poor prognosis and, consequently, there is a significant unmet medical need for an effective treatment.
"We believe that PRX-08066 may be the only 5-HT2B antagonist being developed for PH that has the potential to selectively and safely reduce pulmonary artery blood pressure in these patients without affecting their systemic blood pressure."
Source: Datamonitor
Related Articles
- Patient-Doctor Communication With Patients Who Have High Blood Pressure Is Worse For Blacks Than For Whites
- Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
- Exforge(R) Helps Nearly Twice As Many Patients Control Their High Blood Pressure Compared to Amlodipine Alone
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- Aging Stem Cells Linked to Blood Diseases
- Cancer Support Care May Up Blood Diseases
- Latest Research in Blood Diseases to Be Presented at the Annual Meeting of the American Society of Hematology
- Being Irish Could Kill You ; Celtic Gene Causes Blood Disease
- Genzyme Begins Trial of Myozyme(R) for Patients With Late-Onset Pompe Disease
- Normal Pulmonary Capillary Blood Volume in Patients With Chronic Infiltrative Lung Disease and High Pulmonary Artery Pressure*
 |
 |
User Comments (0)
RSS Feeds